NCT05259020View on ClinicalTrials.gov

To Evaluate the Pharmacokinetics and the Safety of ID14009 Compared to Coadministration of ID1805 With ID1803 in Healthy Adult Volunteers

PHASE1UnknownINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

February 22, 2022

Primary Completion Date

March 30, 2022

Study Completion Date

March 30, 2022

Conditions
DyslipidemiasHypertension
Interventions
COMBINATION_PRODUCT

ID140009

Combination Product: ID140009 Ezetibmibe 10mg/ Rosuvastatin Ca 20.8mg/ Amlodipine 10mg/ Valsartan 160mg

COMBINATION_PRODUCT

ID1803+ID1805

(Amlodipine 10mg/Valsartan 160mg)+(Ezetibmibe 10mg/ Rosuvastatin Ca 20.8mg)

Trial Locations (1)

Unknown

RECRUITING

H plus yangji hospital, Seoul

Sponsors
All Listed Sponsors
lead

IlDong Pharmaceutical Co Ltd

INDUSTRY

NCT05259020 - To Evaluate the Pharmacokinetics and the Safety of ID14009 Compared to Coadministration of ID1805 With ID1803 in Healthy Adult Volunteers | Biotech Hunter | Biotech Hunter